Greenwich Lifesciences Inc (GLSI) Q4 2025 Earnings Call Transcript

Why It Matters

The guidance signals Geron’s ability to scale Rytelo profitably while maintaining financial flexibility, positioning the firm as a growing player in the lower‑risk MDS market.

Key Takeaways

• Rytelo 2025 revenue $184M, 2026 guidance $220‑240M
• Q4 demand grew 9%, prescribing accounts up 13%
• Gross‑to‑net deductions rose to 17.7% in 2025
• Operating expenses projected $230‑240M for 2026
• Cash $400M year‑end; $125M loan available

Pulse Analysis

Geron’s 2025 earnings underscore a pivotal transition from launch to sustainable growth for Rytelo, its telomerase inhibitor targeting transfusion‑dependent anemia in lower‑risk myelodysplastic syndromes. By delivering $184 million in net revenue in its first full commercial year, the company demonstrated that the drug’s inclusion in NCCN guidelines and its positioning as a preferred second‑line option after luspatercept are resonating with hematologists. The modest 9% quarter‑over‑quarter demand lift and a 13% rise in prescribing accounts reflect a disciplined commercial rollout that leverages both high‑volume community practices and targeted digital outreach, a strategy likely to accelerate market penetration as the estimated 8,000 second‑line patients become more identifiable.

Financially, Geron balances growth with prudence. Gross‑to‑net deductions climbed to 17.7% due to broader 340B and GPO participation, a trend that will push net percentages into the high teens or low twenties in 2026. Nevertheless, operating expenses are slated to decline slightly, with a midpoint target of $235 million, driven by lower R&D outlays after approval and a leaner G&A structure following a December 2025 restructuring. The firm’s $400 million cash reserve, bolstered by a $125 million loan facility, provides ample runway to fund commercial expansion, real‑world evidence studies, and over ten investigator‑sponsored trials slated for 2026, reinforcing its long‑term pipeline.

Looking ahead, Geron’s strategic focus on real‑world evidence and investigator‑sponsored trials aims to deepen Rytelo’s clinical profile and support potential label expansions, including earlier‑line indications. The upcoming interim analysis of the IMPACT MF trial could unlock a new revenue stream in myelofibrosis if positive, further diversifying the company’s hematology portfolio. Combined with a clear commercial playbook and solid balance sheet, these initiatives position Geron to capture a larger share of the growing MDS market while laying groundwork for broader hematologic applications.